ERBB2 and breast carcinoma: Patient knowledge regarding individual characteristics of their breast cancer can improve their understanding on recommended treatment strategies (e.g., hormone therapy in cases of hormone‐sensitive disease or trastuzumab in cases with HER2 amplification), which can lead to guideline‐endorsed treatment decisions and greater therapeutic adherence.5